FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2091330377> ?p ?o ?g. }

• W2091330377 endingPage "510" @default.
• W2091330377 startingPage "503" @default.
• W2091330377 abstract "Objective Phase III study to confirm a trend observed in a previous phase II study showing that a single dose of lenercept, human recombinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with severe sepsis or early septic shock. Design Multicenter, double-blind, phase III, placebo-controlled, randomized study. Setting A total of 108 community and university-affiliated hospitals in the United States (60), Canada (6) and Europe (42). Patients A total of 1,342 patients were recruited who fulfilled the entry criteria within the 12-hr period preceding the study drug administration. Intervention After randomization, an intravenous dose of 0.125 mg/kg lenercept or placebo was given. The patient was monitored for up to 28 days, during which standard diagnostic, supportive, and therapeutic care was provided. Measurements and Main Results The primary outcome measure was 28-day all-cause mortality. Baseline characteristics were as follows: a total of 1,342 patients were randomized; 662 received lenercept and 680 received placebo. The mean age was 60.5 yrs (range, 17–96 yrs); 39% were female; 65% had medical admissions, 8% had scheduled surgical admissions, and 27% had unscheduled surgical admissions; 73% had severe sepsis without shock, and 27% had severe sepsis with early septic shock. Lenercept and placebo groups were similar at baseline with respect to demographic characteristics, simplified acute physiology score II-predicted mortality, profiles of clinical site of infection and microbiological documentation, number of dysfunctioning organs, and interleukin-6 (IL-6) plasma concentration. Lenercept pharmacokinetics were similar in severe sepsis and early septic shock patients. Tumor necrosis factor was bound in a stable manner to lenercept as reflected by the accumulation of total serum tumor necrosis factor α concentrations. There were 369 deaths, 177 on lenercept (27% mortality) and 192 on placebo (28% mortality). A one-sided Cochran-Armitage test, stratified by geographic region and baseline, predicted 28-day all-cause mortality (simplified acute physiology score II), gave a p value of .141 (one-sided). Lenercept treatment had no effect on incidence or resolution of organ dysfunctions. There was no evidence that lenercept was detrimental in the overall population. Conclusion Lenercept had no significant effect on mortality in the study population." @default.
• W2091330377 created "2016-06-24" @default.
• W2091330377 creator A5002429988 @default.
• W2091330377 creator A5007050525 @default.
• W2091330377 creator A5007527928 @default.
• W2091330377 creator A5014333112 @default.
• W2091330377 creator A5021550465 @default.
• W2091330377 creator A5032799010 @default.
• W2091330377 creator A5042364388 @default.
• W2091330377 creator A5042409009 @default.
• W2091330377 creator A5043353678 @default.
• W2091330377 creator A5047026139 @default.
• W2091330377 creator A5050393463 @default.
• W2091330377 creator A5057752177 @default.
• W2091330377 creator A5061177278 @default.
• W2091330377 creator A5063814087 @default.
• W2091330377 creator A5069514892 @default.
• W2091330377 creator A5070968814 @default.
• W2091330377 creator A5072678969 @default.
• W2091330377 creator A5076874522 @default.
• W2091330377 creator A5080647333 @default.
• W2091330377 date "2001-03-01" @default.
• W2091330377 modified "2023-10-17" @default.
• W2091330377 title "Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients" @default.
• W2091330377 cites W1588224758 @default.
• W2091330377 cites W1969850821 @default.
• W2091330377 cites W2014123111 @default.
• W2091330377 cites W2019043807 @default.
• W2091330377 cites W2022522156 @default.
• W2091330377 cites W2096824527 @default.
• W2091330377 cites W2108491756 @default.
• W2091330377 cites W2120599813 @default.
• W2091330377 cites W2176899369 @default.
• W2091330377 cites W2325491525 @default.
• W2091330377 doi "https://doi.org/10.1097/00003246-200103000-00006" @default.
• W2091330377 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11373411" @default.
• W2091330377 hasPublicationYear "2001" @default.
• W2091330377 type Work @default.
• W2091330377 sameAs 2091330377 @default.
• W2091330377 citedByCount "268" @default.
• W2091330377 countsByYear W20913303772012 @default.
• W2091330377 countsByYear W20913303772013 @default.
• W2091330377 countsByYear W20913303772014 @default.
• W2091330377 countsByYear W20913303772015 @default.
• W2091330377 countsByYear W20913303772016 @default.
• W2091330377 countsByYear W20913303772017 @default.
• W2091330377 countsByYear W20913303772018 @default.
• W2091330377 countsByYear W20913303772019 @default.
• W2091330377 countsByYear W20913303772020 @default.
• W2091330377 countsByYear W20913303772021 @default.
• W2091330377 countsByYear W20913303772022 @default.
• W2091330377 countsByYear W20913303772023 @default.
• W2091330377 crossrefType "journal-article" @default.
• W2091330377 hasAuthorship W2091330377A5002429988 @default.
• W2091330377 hasAuthorship W2091330377A5007050525 @default.
• W2091330377 hasAuthorship W2091330377A5007527928 @default.
• W2091330377 hasAuthorship W2091330377A5014333112 @default.
• W2091330377 hasAuthorship W2091330377A5021550465 @default.
• W2091330377 hasAuthorship W2091330377A5032799010 @default.
• W2091330377 hasAuthorship W2091330377A5042364388 @default.
• W2091330377 hasAuthorship W2091330377A5042409009 @default.
• W2091330377 hasAuthorship W2091330377A5043353678 @default.
• W2091330377 hasAuthorship W2091330377A5047026139 @default.
• W2091330377 hasAuthorship W2091330377A5050393463 @default.
• W2091330377 hasAuthorship W2091330377A5057752177 @default.
• W2091330377 hasAuthorship W2091330377A5061177278 @default.
• W2091330377 hasAuthorship W2091330377A5063814087 @default.
• W2091330377 hasAuthorship W2091330377A5069514892 @default.
• W2091330377 hasAuthorship W2091330377A5070968814 @default.
• W2091330377 hasAuthorship W2091330377A5072678969 @default.
• W2091330377 hasAuthorship W2091330377A5076874522 @default.
• W2091330377 hasAuthorship W2091330377A5080647333 @default.
• W2091330377 hasConcept C126322002 @default.
• W2091330377 hasConcept C141071460 @default.
• W2091330377 hasConcept C142724271 @default.
• W2091330377 hasConcept C168563851 @default.
• W2091330377 hasConcept C204243189 @default.
• W2091330377 hasConcept C204787440 @default.
• W2091330377 hasConcept C27081682 @default.
• W2091330377 hasConcept C2775965419 @default.
• W2091330377 hasConcept C2777628635 @default.
• W2091330377 hasConcept C2778384902 @default.
• W2091330377 hasConcept C2781300812 @default.
• W2091330377 hasConcept C2992435398 @default.
• W2091330377 hasConcept C71924100 @default.
• W2091330377 hasConceptScore W2091330377C126322002 @default.
• W2091330377 hasConceptScore W2091330377C141071460 @default.
• W2091330377 hasConceptScore W2091330377C142724271 @default.
• W2091330377 hasConceptScore W2091330377C168563851 @default.
• W2091330377 hasConceptScore W2091330377C204243189 @default.
• W2091330377 hasConceptScore W2091330377C204787440 @default.
• W2091330377 hasConceptScore W2091330377C27081682 @default.
• W2091330377 hasConceptScore W2091330377C2775965419 @default.
• W2091330377 hasConceptScore W2091330377C2777628635 @default.
• W2091330377 hasConceptScore W2091330377C2778384902 @default.
• W2091330377 hasConceptScore W2091330377C2781300812 @default.
• W2091330377 hasConceptScore W2091330377C2992435398 @default.
• W2091330377 hasConceptScore W2091330377C71924100 @default.

• next